Unknown

Dataset Information

0

Protective effect of Astragalus membranaceus and Astragaloside IV in sepsis-induced acute kidney injury.


ABSTRACT:

Background

Acute kidney injury (AKI) is the most common target organ damage in sepsis. Sepsis-associated AKI (SA-AKI) may be characterized by damage to the renal tubular epithelium. In this study, the pharmacological mechanisms of Astragalus membranaceus and its active monomer Astragaloside IV (AS-IV) were predicted based on a network pharmacology approach and validated both in vitro and in vivo using the SA-AKI model.

Method

We constructed an in vivo sepsis model using a mouse cecum ligation puncture (CLP) and HK-2 cells were treated with lipopolysaccharide (LPS) to mimic Gram (-) induced sepsis to assess the renal-protective efficacy of Astragalus membranaceus and AS-IV.

Results

The findings demonstrated that Astragalus membranaceus and AS-IV attenuate renal tubular injury in mice with polymicrobial sepsis, including vacuolization, loss of brush border, mitochondrial ultrastructural changes, and increased staining of kidney injury molecule-1 (KIM-1). AS-IV protected human proximal tubular epithelial (HK-2) cells against LPS induced cell viability loss. Both Astragalus membranaceus and AS-IV activated the PI3K/AKT pathway both in vitro and in vivo, as shown by Western blot and immunohistochemistry analysis.

Conclusion

The findings demonstrate that Astragalus membranaceus and AS-IV protect against sepsis-induced kidney tubular injury by activating the PI3K/AKT pathway.

SUBMITTER: Tang JL 

PROVIDER: S-EPMC9365550 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protective effect of Astragalus membranaceus and Astragaloside IV in sepsis-induced acute kidney injury.

Tang Jia-Long JL   Xin Meng M   Zhang Li-Chao LC  

Aging 20220720 14


<h4>Background</h4>Acute kidney injury (AKI) is the most common target organ damage in sepsis. Sepsis-associated AKI (SA-AKI) may be characterized by damage to the renal tubular epithelium. In this study, the pharmacological mechanisms of Astragalus membranaceus and its active monomer Astragaloside IV (AS-IV) were predicted based on a network pharmacology approach and validated both <i>in vitro</i> and <i>in vivo</i> using the SA-AKI model.<h4>Method</h4>We constructed an <i>in vivo</i> sepsis m  ...[more]

Similar Datasets

| S-EPMC11226570 | biostudies-literature
| S-EPMC8240166 | biostudies-literature
| S-EPMC5316919 | biostudies-literature
| S-EPMC5583140 | biostudies-literature
| S-EPMC6563000 | biostudies-literature
| S-EPMC3703719 | biostudies-literature
| S-EPMC6122638 | biostudies-literature
| S-EPMC7055075 | biostudies-literature
| S-EPMC9792096 | biostudies-literature
| PRJNA336067 | ENA